<DOC>
	<DOCNO>NCT01384526</DOCNO>
	<brief_summary>Ovarian toxicity well-described side effect traditional chemotherapy premenopausal woman receive treatment early stage breast cancer . However , impact long-term endocrine therapy ovarian function establish , knowledge , never directly study . Understanding effect hormone therapy ovarian age help breast cancer patient reproductive age make inform empowered decision regard treatment . The purpose study explore relationship tamoxifen therapy ovarian aging . Patients identified UCSF Cancer Registry California Pacific Medical Center Cancer Registry evaluate base age menopausal status . Women read study clinicaltrials.gov contact study coordinator also consider enrollment . The age menopause onset assess survey compare accepted national average age natural menopause . Biomarkers ovarian reserve assess premenopausal woman age 25-45 compare healthy age- ethnicity-matched premenopausal control ongoing RO1- fund prospective longitudinal ovarian aging ( OVA ) study .</brief_summary>
	<brief_title>Investigating Impact Tamoxifen Therapy Ovarian Aging</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Inclusion Criteria 1 . Female 2 . â‰¥25 year age time study enrollment 3 . Diagnosed stage IIII invasive breast cancer ductal carcinoma situ , determine high risk primary breast cancer 4 . If endocrine therapy use , woman must complete least 2 year endocrine therapy define either 1 . Tamoxifen alone 2 . Ovarian suppression plus tamoxifen aromatase inhibitor 3 . Ovarian suppression alone 5 . Women must premenopausal time endocrine therapy initiation . Premenopausal define menstrual cycle within 12 month start treatment . 6 . For biomarker assessment , patient must endocrine therapy ( tamoxifen , ovarian suppression goserelin leuprolide , aromatase inhibitor ) least 6 month prior study enrollment . 7 . For biomarker assessment , patient must hormone contraceptive , fertility treatment , hormone therapy least 3 month prior study enrollment 8 . For biomarker assessment , patient must regular period last 3 month . Exclusion Criteria 1 . Evidence either local recurrence follow use adjuvant systemic therapy evidence distant recurrence breast cancer . 2 . Prior history ovarian surgery manipulation 3 . Mother premature ovarian failure define onset menopause age &lt; 40 4 . Prior chemotherapy exposure 5 . Prior history endometriosis , anovulation document infertility 6 . Pregnant time study enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>hormone therapy</keyword>
	<keyword>ovarian age</keyword>
	<keyword>ovarian reserve</keyword>
	<keyword>fertility</keyword>
	<keyword>breast cancer</keyword>
</DOC>